non-opioid pain drugs
Latigo saddles up with $150M to spur non-opioid pain drugs through the clinic
Latigo Biotherapeutics, non-opioid pain drugs, Nav1.8 inhibitors, Series B funding, clinical trials, acute pain, chronic pain
Actionable Insights Powered by AI
Latigo Biotherapeutics, non-opioid pain drugs, Nav1.8 inhibitors, Series B funding, clinical trials, acute pain, chronic pain